title: Hyperbaric oxygen therapy in idiopathic sudden sensorineural hearing loss (ISSNHL) in association with combined treatment.
abstract: The main basic effect of hyperbaric oxygenation (HBO2) on the human body, in our study, was an increased partial pressure of oxygen resulting from an increased amount of oxygen dissolved in plasma. Thus the plasma can become capable of carrying enough oxygen to meet the needs of the body's tissues. From 1 January 2004 to 31 December 2007, a total of 61 patients (62 ears) received medical treatment at the ENT clinic of the 3rd Faculty of Medicine, Charles University, and at the Central Military Hospital in Prague. Treatment consisted of a combination of vasodilatation infusion treatment and HBO2 therapy. The results were evaluated in a retrospective study. The overall percentage of patients showing improvement was 59.7%. However, for those patients who started HBO2 treatment within 10 days of onset, complete recovery, or significant improvement was noted in 65.9%. In contrast, patients who started treatment after 10 days of onset, improvement was noted in only 38.9%. NMR examination revealed that two patients had vestibular schwannoma (also known as acoustic neuroma).
authors.affiliation: ENT Clinic, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic. richard.holy@uvn.cz
authors.forename: R
authors.initials: R
authors.lastname: Holy
authors.forename: M
authors.initials: M
authors.lastname: Navara
authors.forename: P
authors.initials: P
authors.lastname: Dosel
authors.forename: P
authors.initials: P
authors.lastname: Fundova
authors.forename: P
authors.initials: P
authors.lastname: Prazenica
authors.forename: A
authors.initials: A
authors.lastname: Hahn
mesh_terms: D000328:Adult; D000368:Aged; D001299:Audiometry; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006319:Hearing Loss, Sensorineural / Q000209:etiology / Q000628:therapy*; D003639:Hearing Loss, Sudden / Q000209:etiology / Q000628:therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation / Q000379:methods*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D010100:Oxygen / Q000097:blood*; D010313:Partial Pressure; D010431:Pentoxifylline / Q000008:administration & dosage; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014664:Vasodilation; D014665:Vasodilator Agents / Q000008:administration & dosage*; D014748:Vinca Alkaloids / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine; D010100:Oxygen; D010431:Pentoxifylline; D008775:Methylprednisolone